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inflammation and fibrosis. Overall, our data suggest that HKDC1 expression in hepatocytes results in defective mitochondrial function and altered hepatocellular metabolism and speculate that its expression in the liver may play a role in the development of NAFLD. (Endocrinology 160: 313-330, 2019) G lucokinase (GCK) is one of the four well-established mammalian hexokinases (HKs) and is characterized by its high Michaelis-Menten constant (Km) and glucose-sensing role in the pancreas and liver (1) . The other HKs, HK1-3, have lower Km and in general, play a central role in nonglucose-sensing tissues to drive glucose metabolism. HKs, such as GCK, catalyze the first committed step in glycolysis, phosphorylating glucose to yield the product glucose-6-phosphate (G6P) (2) . In the liver, GCK contributes 95% of HK activity measured in hepatocytes. The product, G6P, can then enter the various anabolic and catabolic pathways, such as lipid synthesis and glucose oxidation, respectively (1, 3) . However, in altered hepatic metabolic states, such as those seen in hepatocellular carcinoma, diabetes, and fatty liver, GCK expression and function are considerably altered (4) (5) (6) (7) (8) . As an example, in liver cancer, one of many reported changes that promotes the Warburg effect is an isozyme switch that occurs from GCK to HK2 and HK1 (to a lesser extent) (7, 8) . Moreover, studies have demonstrated that GCK overexpression promotes hepatic fat accumulation in rodents and is positively correlated with fatty liver disease in humans (7, 9) . Besides liver cancer, the role of other HK isozymes in normal physiological states and in liver pathologies has not been studied extensively.
Our group recently proposed HK domain-containing 1 (HKDC1) to be a fifth HK that was initially identified to be associated with maternal hyperglycemia during pregnancy in a genome-wide association study (10, 11) . We have reported that HKDC1 expression contributes to cellular HK activity (11, 12) . Moreover, we generated mouse models-HKDC1 global knockout mice-which are observed to be embryonic lethal, as no mice with both HKDC1 alleles deleted have been generated for over 5 years of breeding. Thus, our first characterization was in mice with heterozygous deletion of Hkdc1. We observed that partial loss of Hkdc1 expression impairs glucose clearance (with aging and during pregnancy) and reduces tissuespecific glucose disposal and hepatic triglycerides levels (12) . These data suggest that Hkdc1 may play an important role in glucose homeostasis and hepatic lipid accumulation, and this may be through a role in the liver. Multiple substantial questions remain to be answered about the function and influence of HKDC1 on metabolism.
Therefore, we sought to characterize first HKDC1 more extensively by exploring its HK function and impact on cellular metabolism and to understand whether HKDC1 has a role in hepatic metabolism. We found HKDC1 to have very low activity, less than any of the existing HK isozymes. As HKs interact with the mitochondria via their N-terminal domain sequence, which is thought to impact their cellular role (13) (14) (15) , we observed that HKDC1 also colocalizes with the mitochondria and likely by its N-terminal domain sequence as well. With the examination of whether HKDC1 expression impacts hepatocyte metabolism, we overexpressed human HKDC1 in mouse hepatocytes that resulted in a reduction in glucose oxidation and mitochondrial membrane potential, and acute in vivo overexpression of HKDC1 in the liver increased the mitochondrial fission marker dynamin-related protein 1 (DRP1), all suggesting that HKDC1 overexpression induces a defect in mitochondrial function. We further observed that in vivo overexpression does not substantially change hepatic energy storage but modestly improves glucose homeostasis. Lastly, as partial deletion of HKDC1 led to reduced fat in the liver, we tested whether the expression is induced in humans and mice-modeling characteristics of nonalcoholic fatty liver diseases (NAFLDs), observing an association between HKDC1 expression and aspects of NAFLD.
Materials and Methods

Human studies
Liver biopsy samples
Liver biopsy samples were obtained from S.H. (Division of Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, TX). Liver samples for the percentage of steatosis had stage 1 fibrosis only and included 16 male and four female subjects (steatosis across group ranged from 10% to 66%). Samples for the stages of fibrosis included 29 male (72.5% of sample size) and 11 female subjects (27.5% of sample size) with varying amounts of steatosis. The samples were RNA extracted and purified, and quantitative PCR (qPCR) was performed as described below.
Immunohistochemistry
The liver specimens were obtained from X.D. (Department of Pathology, Loyola University Chicago, Maywood, IL) and were surgical pathology or autopsy cases from the Department of Pathology, from 2014 to 2016, with Institutional Review Board approval (#207299) and prepared as published (16) . All cases examined here had no clinical history of alcohol and hepatotoxic medication intake. Serum ceruloplasmin, a1-antitrypsin, and ferritin levels were within normal ranges. All cases had negative serological tests for anti-nuclear antibody, anti-smooth muscle actin antibody, anti-mitochondrial antibody, hepatitis B, and hepatitis C. The specimens included normal liver, NAFLD, and nonalcoholic steatohepatitis (NASH), with and without cirrhosis. Assessment of the degree of steatosis was based on a semiquantitative scale by evaluation of the percentage involvement of parenchyma, which is expressed as grades (grade 1: 5% to 33%, grade 2: .33% to 66%, and grade 3: .66%). Ballooned hepatocytes (an essential histologic feature of steatohepatitis) are characterized by enlarged hepatocytes with rarefied reticulated cytoplasm and with or without fat droplets and Mallory-Denk bodies. Hepatocyte ballooning was scored based on the frequency of ballooning cells (grade 0 if rare and grade 1 if it is easily identified microscopically). The hematoxylin and eosin (H&E) stains and immunohistochemistry were reviewed and scored by a histologist (X.D.), and representative images are shown based on his review (17) .
Animals
All mice were obtained from The Jackson Laboratory and housed under a 12-hour light, 12-hour dark cycle with ad libitum access to normal chow (Envigo), unless otherwise noted. All mouse studies were approved by Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals at both Northwestern University and the University of Illinois at Chicago.
Mouse diets
High-fat, high-fat high-glucose, high-fat high-sucrose diets A subset of 8-week-old mice were fed for 20 weeks on the various diets, as indicated in "Results." Additionally, mice on high-fat (HF) + high-fructose (HFr) were analyzed for Hkdc1 expression and triglycerides after 2, 4, or 6 months on the diet, starting at 2 months of age. HF diet contents were 60% Kcal from fat (Research Diets). HF + HFr, Sucrose diet contents were 58% Kcal fat, 25.5% carbohydrate, and 16.4% protein (OpenSource Diets; D12331). HF + high-glucose (HG; corn starch) diet contents were 58% Kcal fat, 25.5% carbohydrate, and 16.4% protein. HF + HFr and HF + HG diets were additionally supplemented with fructose/sucrose or glucose in the water.
Additional diets
Ten-week-old chow-fed male C57Bl6/J (B6) mice were obtained from The Jackson Laboratory and bred in house. Mice were injected with a single dose of AAV8-TBGp-Null (1.5 $ 10e11 genome copies) in the lateral tail vein and used as wildtype mice. Two weeks later, mice were switched to different diets. The methinonine-and choline-deficient diet (MCD; catalog no. A02082002BR; Research Diets) and methinonine-and choline-supplemented diet (MSD; catalog no. A02082003BY; Research Diets) were fed to the mice for 3 weeks, after which, the mice were euthanized. Both diets are nutrient-and energy-content matched. MSD and MCD have 20% Kcal from fat (corn oil). The HF, methinonine-restricted, and choline-deficient diet (CDA-HFD; catalog no. A06071302; Research Diets) and the HF, methinonine-restricted, and choline-supplemented diet (MSD-HFD; catalog no. A06071306; Research Diets) were fed to the mice for either 3 or 6 weeks, after which, the mice were euthanized. Both diets are nutrient-and energy-content matched. Source of fat is mostly lard. The HF (40% Kcal from fat), high-cholesterol (2%), and HFr (HFCF; 20% Kcal) diet (catalog no. D16010101; Research Diets) and the low-fat, low-cholesterol, and low-fructose diet (LFCF) diet (catalog no. D09100304; Research Diets) were fed to the mice for 8 weeks, after which, the mice were euthanized.
Adenovirus construction
Adenovirus construction was produced, as described in Guo et al. (11) and Becker et al. (18) .
In vivo transduction of adenovirus containing human HKDC1 or GFP Mice were injected with 10 9 viral particles of adenovirus containing either human HKDC1 (Ad-HKDC1) or green fluorescent protein (Ad-GFP) via the penile vein at 10 to 12 weeks of age. Mouse tissues were harvested 7 to 10 days postinjection for end-point analyses.
Metabolites
Mice were fasted for 16 hours overnight and the following metabolites were measured: glucose, insulin, nonesterified fatty acid (NEFA) levels, and triglycerides. For glucose, blood was obtained from tail veins and measured with a One-Touch Ultra Glucometer. Blood was also obtained from tail vein using heparinized capillary tubes and centrifuged at 8000 rpm for 15 minutes for serum collection. Insulin levels were then determined by an ELISA (ALPCO). NEFA levels were measured following the manufacturers' instructions (Wako Diagnostics, Richmond, VA). Triglycerides were determined using Infinity Triglyceride Solution (Thermo Fisher Scientific).
Hepatic triglycerides and glycogen
Animals were unfed for 16 hours overnight and were either euthanized or then refed for 4 hours before being euthanized. Harvested livers were immediately flash frozen in liquid nitrogen and then stored at 280°until analyses were performed. For triglycerides, livers were homogenized on ice using a glass douncer and PBS. Homogenates were cleared by centrifugation at 13,000 rpm, and the supernatant was collected. Hepatic triglycerides were determined using Infinity Triglyceride Solution (Thermo Fisher Scientific). For glycogen, flash-frozen liver samples were either determined using the Glycogen Assay Kit (SigmaAldrich; MAK016-1KT) or analyzed by 13 C-nuclear magnetic resonance for glycogen levels at the Yale Mouse Metabolic Phenotyping Center (Yale University, New Haven, CT).
Histology
Sections of liver were either embedded in optimal cutting temperature (OCT) or paraffin. In brief, for OCT, a section of the liver was stored in 4% paraformaldehyde (PFA) for 1 hour at room temperature and subsequently washed in PBS. After the washes, the liver sections were subjected to a sucrose gradient and then stored in 10% sucrose at 4°C overnight. The next day, liver sections were embedded in OCT and stored in 280°C. For paraffin embedding, liver sections were fixed in 4% PFA for 24 hours at room temperature. The next day, sections were washed in 50% ethanol and then stored in 70% ethanol until embedding in paraffin. For image analysis, Fiji (ImageJ) software was used for analysis of Oil Red O, PAS, and DPAS stains. For Oil Red O, tiff files were converted into 32-bit images, and the threshold was set to select the Oil Red O intensity of each image. Once threshold was performed, pixel intensity was measured, along with image area. The image intensity divided by the area gave a quantification of Oil Red O staining intensity per image. An ImageJ macro was created to quantify multiple images systematically. For PAS, the stain was quantified using the same method as for Oil Red O. For DPAS, tiff files were converted into 32-bit images, and inverted color threshold was used to quantify the white-pixel intensity and area of each image file. The white area represented the amount of PAS stain that was removed, which was a quantification of glycogen that was removed by diastase. DPAS measurement was divided by the PAS stain to obtain the amount of glycogen per group.
Glucose and insulin tolerance test
IP glucose tolerance tests (IPGTTs) were performed on mice unfed for 16 hours overnight with glucose given by IP injection at a dose of 2 g glucose/kg body weight. Glucose levels were measured by the tail vein, as mentioned above, and taken at multiple time points (from 0 to 120 minutes) during the IPGTT. Area under the curve (AUC) values were calculated by standard approaches using the trapezoidal rule and represented as means 6 SEM. Additionally, blood was collected at 0 and 15 minutes in heparinized capillary tubes and centrifuged at 8000 rpm for 15 minutes to collect the serum. Insulin levels in these samples were determined as mentioned above. Insulin tolerance tests (ITTs) were performed on mice unfed for 6 hours and then IP injected with 0.75 U/kg body weight of Humalog insulin (Eli Lily & Co). Blood glucose levels were determined similarly as the glucose tolerance tests.
Lentivirus construction in MI5-4 Chinese hamster ovary cells
Dr. Nissim Hay kindly provided MI5-4 Chinese hamster ovary (CHO) cells [RRID: CVCL_IP24 (19) ]. These CHO cells were cultured in a-minimum essential medium (Cellgro) and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Lentivirus production was performed according to Addgene's protocol. In brief, pLenti6-D-TOPO vector, containing rat HK2, human GCK, or human HKDC1, was cotransfected with both psPAX2 and pMD2.G into 293 T cells. Transduction was performed overnight in the presence of polybrene without antibiotics. Blasticidin (10 mg/mL) was then used for selection of successfully transduced cells.
RNA isolation and qPCR
RNA was extracted from 10 mg livers using TRIzol reagent (Life Technologies) and chloroform for phase separation. RNA was then purified using the RNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase (Qiagen). Purified RNA (1 mg) was then reverse transcribed using qScript Reverse transcription (Quanta Biosciences) and quantified via qPCR using PerfeCTa SYBR Green SuperMix (Quanta Biosciences), where final primer concentrations were 0.625 mM for each reaction, and data were analyzed via the CFX Connect Real-Time PCR Detection System (Bio-Rad).
HK activity assay
HK microplate assays for purified HKs
To assay HK activity, 2 mg-purified, full-length HK proteins or C-and N-terminal domains of HKDC1 separately were diluted in 20 mL HK dilution buffer [20 HK assay using lentiviral MI5-4 CHO cells HK activity was determined, as previously described (20) . In brief, 8 3 10 6 cells were plated on 6-cm dishes and allowed to attach overnight. The next day, cells were washed once with PBS and harvested by scraping and pelleted at 4000 rpm for 5 minutes. Cells were lysed by sonication, five pulses of 1 second, in 100 ml homogenization buffer: 0.2% Triton X-100, 0.5 mM EGTA, 10 mM D-(+)-glucose, 11.1 mM monothioglycerol, 45 mM Tris-HCl (pH 8.2), and 50 mM KH 2 PO 4 . After sonication, lysates were centrifuged at 8000 rpm for 5 minutes. HK activity was determined by the whole-cell lysate's ability to phosphorylate glucose over 2 minutes in an assay mixture with final concentrations of 50 mM triethanolamine chloride, 7.5 mM MgCl 2 , 0.5 mM EGTA, 11 mM monothioglycerol, 0.5 to 25 mM glucose, 6.6 mM ATP, 0.5 mg/mL NADP, and 0.5 U/mL G6PDH, pH 8.5. G6P formation was measured indirectly by NADPH production from G6PDH by measuring absorbance at 340 nm on a spectrophotometer and was normalized to protein concentration as determined using the Bio-Rad protein Assay Dye Reagent Concentrate.
Protein purification
Protein was purified, as previously described (11) . In brief, Rosetta 2 (DE3; EMD Millipore) cells were transformed with pReceiver-B01 plasmid containing HKDC1, HK1, or GCK.
) (100 mL) containing 50 mg/mL ampicillin and 34 mg/mL chloramphenicol were inoculated with a single colony and grown overnight at 37°C. The pregrowth culture was added to 500 mL of the same media and grown to an OD of ;0.6. Protein expression was induced at room temperature by adding isopropyl b-D-1-thiogalactopyranoside to a final concentration of 1 mM and grown for an additional 4 hours. Cultures were centrifuged at 10,000g for 30 minutes and resuspended in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 0.25% Tween 20, 5% sucrose, 5% glycerol, 2 mM imidazole), supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 mg/mL aprotinin, 0.5 mg/mL leupeptin, 0.7 mg/mL pepstatin A). Cells were sonicated on ice for 5 minutes, followed by DNase I treatment (4 U/mL) for 15 minutes. Lysates were clarified by centrifugation at 10,000g for 30 minutes, and the supernatant was passed over a HisTALON column (Clontech). The column was washed with 25 mL wash buffer (lysis buffer, pH 7.0, 25 mM imidazole). Protein was eluted from the column in 1-mL fractions using wash buffer with 500 mM imidazole. DTT was added to a final concentration of 1 mM.
Western blot
HK activity blots
After the performance of HK activity assays, whole-cell lysates were stored for Western blotting. Equal amounts of protein were loaded on an 8% SDS-PAGE gel and resolved by electrophoresis. Protein was transferred to a polyvinylidene fluoride (Bio-Rad) membrane. Membranes were blocked in 5% milk/Tris-buffered saline-Tween 20, and both primary and secondary antibody incubations were performed in 2.5% milk/ Tris-buffered saline-Tween 20. All primary antibodies were incubated overnight at 4°C, except hemagglutinin (HA), which was incubated for 45 minutes. Secondary incubations were done for 90 minutes at room temperature. 
Mitochondrial dynamics blots
Proteins were separated using 10% SDS-polyacrylamide gels and transferred to nitrocellulose membrane and blocked for 1 hour at room temperature in PBS with 0.1% Tween (PBST) containing 5% nonfat dry milk. Membranes were then probed with the appropriate primary antibody: mitofusion ( 
Hepatocyte isolations and multiplicity of infection adenovirus addition
Mouse hepatocytes were isolated based on a two-step collagenase perfusion protocol, as referenced in Severgnini et al. (33) . In brief, mice were anesthetized with 5 U of a mixture of ketamine (90 mg/kg) and xylazine (5 to 10 mg/kg). An abdominal incision was made to expose the liver and portal vein. An IV catheter was inserted into the portal vein and perfused with Hanks' balanced salt solution buffer without phenol red (Corning) and then perfused with collagenase from Clostridium histolyticum (Sigma-Aldrich), diluted in DMEM (Gibco). Livers were then removed and torn gently apart for the release of hepatocytes. Cells were then washed with DMEM and plated. After 4 hours of the allowance of hepatocytes to attach, adenoviruses were added for 4 hours or overnight at a multiplicity of infection (MOI) of 5 to 10 in serum-free DMEM.
Construction of plasmids
GFP-tagged plasmids
To generate the full-length and truncated GFP-HKDC1 plasmids, In-Fusion cloning PCR primers were designed to the first or second exon of the 2754-bp fragment from the pReceiver-B01 containing HKDC1. To perform the In-Fusion reaction, the PCR primers also contained overhang regions for XhoI and BamHI-HF restriction enzyme sites and a 15-bp homology portion to the plasmid enhanced GFP-N3 (Addgene) vector to facilitate recombination.
HA-tagged plasmids
Rat HK2 or human GCK cDNA was subcloned into the pcDNA3-HA vector. The HA-tagged cDNAs were then further subcloned into the pLenti6-D-TOPO vector (Invitrogen). HKDC1 was subcloned by Gibson assembly, where briefly, HKDC1 was amplified from plasmid enhanced GFP-N3-fulllength HKDC1 (as described above).
FLAG-tagged HKDC1 plasmid
Human HKDC1 cDNA was cloned into pCMV6-XL4 containing a Myc-DDK tag (HKDC1-FLAG; Origene).
Confocal imaging
Glass-bottom confocal dishes (35 mm; VWR) were coated with 60 nM fibronectin (Sigma-Aldrich), diluted in 0.1% gelatin overnight. Before plating cells, confocal dishes were washed twice with PBS. Hepatocytes were plated on collagencoated, six-well plates with coverslips (for immunofluorescence) or without [for tetramethylrhodamineethylester (TMRE) colocalization] for 2 hours and then transfected using TargefectHepatocyte (Targetingsystems) following the manufacturer's instructions. In brief, 5 mL GFP-N3 control, HKDC1 full-length GFP, or HKDC1-truncated GFP plasmid DNA was added to 600 mL OptiMEM and vortexed for 30 seconds, and then 8 mL Targefect reagent was added to the DNA-OptiMEM mix and vortexed for 30 seconds, followed by addition of 8 mL Virofect enhancer reagent. After the transfection mix was incubated in a 37°C water bath, 600 mL of the transfection mix was added to each confocal dish and incubated for 2 hours. After a 2-hour incubation, 1.4 mL either 25 or 5.5 mM DMEM (supplemented with 2 mM glutamine and 2 mM sodium pyruvate) was added to the confocal dishes. Twenty-four hours after transfection, media were changed to fresh DMEM with either 25 or 5.5 mM glucose.
TMRE colocalization
Hepatocytes were washed with PBS and changed to either 25 or 5.5 mM glucose confocal buffer (1.8 mM CaCl 2 , 2.5 mM KCl, 140 mM NaCl, 2 mM sodium pyruvate, 2 mM glutamine, 20 mM HEPES, pH 7.5, 1 mM MgCl 2 ). Hepatocytes were then stained with 5 nM TMRE (for mitochondrial stain) and two drops/mL NucRed Live 647 ReadyProbes (Thermo Fisher Scientific) for 20 minutes. Hepatocytes were then washed with PBS, and fresh 25 or 5.5 mM glucose confocal buffer was added. TMRE (red channel) and GFP (green channel) signals were analyzed for colocalization using ImageJ. Coloc-2 function was used to determine Pearson correlation coefficient and was calculated for 19 to 27 cells.
Immunofluorescence colocalization with voltage-dependent anion channel
Forty-eight hours post-transfection, cells were fixed in 4% PFA in PBS for 10 minutes at room temperature. Cells were then washed in PBS and stored at 4°C overnight. The next day, cells were permeabilized in 0.1% Triton X-100 in PBS for 10 minutes at room temperature. Cells were then blocked in 5% goat serum in 0.1% Triton X-100 in PBS for 1 hour, after which, they were incubated in 1:150 voltage-dependent anion channel (VDAC) antibody [Thermo Fisher Scientific; catalog no. PA1-954A, RRID: AB_2304154 (34)], at 4°C overnight. The antibody was validated by Thermo Fisher Scientific (35) and Polyzos et al. (36) . The next day, cells were washed three times in PBST for 10 minutes at room temperature, after which, they were incubated in 1:200 secondary antibody Alexa Fluor 594 AffiniPure goat anti-rabbit [H+L; Jackson ImmunoResearch Laboratories; catalog no. 111-585-144, RRID: AB_2307325 (37)] for 2 hours at room temperature protected from light. Cells were then rinsed with PBST and then incubated with 20 nM Hoechst 33342 Solution (Thermo Fisher Scientific; 62249) for 10 minutes at room temperature. Coverslips were then mounted on slides and left to dry overnight.
Hepatocytes were imaged using an LSM510 META laserscanning confocal microscope (Zeiss Instruments). Multichannel laser setting was used to image GFP (Ex/Em 488/ 510 nm), TMRE (Ex/Em 549/575 nm), NucRed (Ex/Em 638/ 686 nm), and Alexa Fluor 594 (Ex/Em 591/614 nm). VDAC (red channel) and GFP (green channel) signals were analyzed for colocalization using ImageJ. Coloc-2 function and Pearson correlation coefficients were calculated for 15 to 21 cells.
Mitochondrial membrane potential measurement
Confocal images of hepatocytes overexpressed with GFPtagged empty vector (EV), HKDC1 full length, and HKDC1 truncated in 25 mM glucose media were stained with 5 nM TMRE in Hanks' balanced salt solution in a non-CO 2 37°i ncubator for 15 minutes, and its fluorescence intensity was measured using ImageJ. Pixel intensity was normalized to area for each individual cell expressing GFP.
Oxygen consumption rate and extracellular acidification rate
Hepatocytes were plated onto XFe96 plates for 4 hours before media change into DMEM 10% FBS overnight. The media were then replaced with serum-free DMEM with respective adenoviruses to an MOI of five. Media were changed 6 hours later to the baseline Seahorse media. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using an XFe96 extracellular flux analyzer (Seahorse Bioscience). Basal mitochondrial respiration was measured by the attainment of the initial OCR readings and subtraction of the OCR values after treatment with 10 mM antimycin A and 10 mM rotenone (Sigma-Aldrich). Maximal respiration was measured by the subtraction of the nonmitochondrial respiration by the maximum rate measurement after 1 mM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) injection. Glycolysis was determined by subtraction of the last rate measurement before glucose injection by the maximum rate measurement before oligomycin injection. Glycolytic capacity was measured by subtraction of the last rate measurement before glucose injection by the maximum rate measurement after oligomycin injection. 2-Deoxyglucose (Sigma-Aldrich; 50 mM) was used to return ECAR to baseline. Experiments were performed in DMEM with no glucose or bicarbonate containing 2 mM glutamine (Sigma-Aldrich).
Coimmunoprecipitation
Human embryonic kidney 293-T cells were transfected with HKDC1-FLAG plasmid using Lipofectamine reagent (Thermo Fisher Scientific), and whole-cell lysates were collected after 48 hours. Lysates were then immunoprecipitated using Anti-FLAG M2 affinity gel (EZview Red Anti-FLAG M2 Affinity gel; Sigma-Aldrich). Eluted samples were given to the Northwestern Proteomics Core using the 100-minute gradient tandem mass spectrometry Orbitrap.
Radioactivity
14
C-Labeling experiments were carried out, as previously described, with some modifications (38) . Hepatocytes were plated on collagen-coated, six-well tissue-culture plates. The hepatocytes were allowed to attach for 4 hours, and adenovirus containing human HKDC1 or GFP was then supplemented for an additional 4 hours, after which, the media were changed to 25 mM glucose DMEM, supplemented with 10% FBS for 16 hours (overnight).
b oxidation Cells were glucose starved for 2 hours, and 0.5 to 1 mCi radiolabeled 1-14 C palmitic acid (Perkin Elmer) was added to the growth media at the end of the 2 hours. A Whatman chromatography paper, cut to the size of a six-well plate, was soaked in 3 M NaOH and placed on the lid of the plate, such that each well was properly covered to ensure trapping of any released CO 2 . The cells were incubated at 37°C for 2 hours. Following the incubation, 500 mL 70% perchloric acid was added to each well, and the released CO 2 was trapped in the Whatman paper for 1 hour. The filter paper was left for drying overnight, and the 14 C levels were estimated using a b-counter (Perkin-Elmer). Cells were then scrapped and pelleted down after a brief centrifugation at 5000g for 5 minutes at 4°C. The pellet was then washed twice with 13 PBS and lysed using 0.5 N NaOH, vortexed, and centrifuged to isolate the cell lysate at 18,000g for 10 minutes at 4°C. Experiments were carried out in quadruplicate and normalized to total cellular protein.
Glucose oxidation
Cells were glucose starved for 2 hours, and 0.5 to 1 mCi radiolabeled U- 14 C glucose (Perkin Elmer) was added to the growth media at the end of 2 hours and carried out as described above.
De novo lipogenesis
Incorporation of radiolabeled acetate or glucose in cells via the lipogenesis pathway was carried out using 14 C-labeled acetate or glucose. Cells were glucose starved for 2 hours, and 1 mCi 1,2-14 C acetic acid (Perkin Elmer) or 0.5 to 1 mCi radiolabeled U-14 C glucose (Perkin Elmer) was added to the growth media at the end of 2 hours. At the end of 2 hours, cells were washed with warm 13 PBS, three times, and total intracellular lipids were extracted with a hexane and 2-propanol [3:2 (vol/vol)] mixture. Incorporation of carbons from 1,2-14 C acetic acid or U-14 C glucose into the lipid phase was assayed by scintillation counting and carried out as described above.
HKDC1 structure
An HKDC1 structural homology model was created using the Phyre2 web portal for protein modeling, prediction, and analysis and superimposed on human HK1 (Protein Data Bank 1hkc) complexed with glucose and phosphate using PyMOL2.0.
Statistical analysis
Data are presented as means 6 SEM. All data were compared by a two-tailed unpaired Student t test for statistical significance or one-way ANOVA multiple comparisons (GraphPad Prism), as specified in the figure legends.
Results
HKDC1 has reduced HK activity but colocalizes with mitochondria as other HKs
We began by examining the kinetic properties of HKDC1 by purification of recombinant human HKDC1 and performance of HK activity assays alongside GCK and HK1. Although we are able to approximate the Km for both GCK and HK1, we could not determine the Km of HKDC1 as a result of its low level of activity (Fig. 1A ). Additionally, we tested different experimental conditions that may affect its activity, such as the use of different nucleotides, ATP, and Mg 2+ concentrations, but observed similar low-affinity HK activity for HKDC1 (17) . Furthermore, given that the catalytic activity of HK1 is confined to the C-terminus, and allosteric regulation occurs at the N-terminus (39), we explored if the interdomain interaction of HKDC1 was interfering with its overall activity. However, after the purification of the Nand C-terminal domains and running of the HK activity assays separately, we observed similar low-affinity HK activity as seen with the intact, full-length protein (17) . We next wanted to examine the contribution of HKDC1 to overall cellular HK activity, as it is possible that HKDC1 requires post-translational modifications or proteinbinding partners. We generated a stable HKDC1 overexpression cell line in MI5-4 CHO cells [an established line with minimal HK activity (40)] for exclusive determination of HKDC1 activity with minimal contribution from other HKs in examining HK activity. HKDC1 produced a substantial but only modest amount of total HK activity compared with the EV stably overexpressed line at all concentrations of glucose (Fig. 1B) (17) .
As previously reported, HKDC1 shares 71% sequence identity with HK1 (2). Given this high-sequence homology, it was surprising to find that HKDC1 did not have similarly high activity. Therefore, to elucidate any salient structural differences that may account for the low activity observed, we obtained a predicted structural model of HKDC1 (98% of the residues were modeled with 100% confidence) using the Phyre2 web portal (41) and superimposed this model onto human HK1 using PyMol2.0 (Fig. 1C) . Interestingly, the HKDC1 model aligned an appreciable amount with HK1 with similar positioning of the amino acids necessary for allosteric interdomain communication and for carrying out catalysis (39) . However, we noted a few deviations between some of the key amino acid residues involved in the allosteric ( Fig. 1D and 1E ) and catalytic (Fig. 1F) sites. For two of the main salt bridges involved in interdomain communication in HK1, the distance between the residues for both HK1 and HKDC1 are the same; however, there is a shift of 4.4Å (Fig. 1D ). In the second site, the distance between the interaction of the residues is less for HKDC1 than that of HK1, and there is an additional 4.7Å shift (Fig. 1E) . Similar patterns were seen in the catalytic active site, where the distance between the key amino acids involved were ;2.1Å closer for HKDC1 and a notable 8.5Å shift from HK1 at its widest point. These structural differences between HKDC1 and HK1 in key residues involved in the catalytic and allosteric sites may impact the enzymatic activity of HKDC1.
In addition to their activity differences, HK isozymes are reported to have particular protein-binding partners and subcellular localization preferences that define their role in glucose metabolism (42) ; therefore, we first determined potential binding partners of HKDC1 by overexpressing FLAG-tagged human HKDC1 in human embryonic kidney 293 cells. Interestingly, mass spectrometry analysis from the coimmunoprecipitation showed that HKDC1 might be associated with the outer mitochondrial membrane proteins VDAC1 and VDAC2, canonical mitochondrial binding partners of HK1 and HK2 (17, (42) (43) (44) (45) . As the other HKs (HK1 and HK2 only) contain an N-terminal mitochondrial localization sequence region, we observed that human and mouse HKDC1 also share sequence similarity in this region of the protein (Fig. 2A) . Moreover, the HK isozymes are reported to interact with VDAC through this region (20) (21) (22) (23) . Because of this, we sought to determine whether HKDC1 localizes to the mitochondria via its N-terminal sequence in hepatocytes. Therefore, we transfected primary mouse hepatocytes with plasmid that contains GFPtagged full-length HKDC1 and GFP-tagged N-terminal truncated HKDC1 (first 20 residues that serve to bind to mitochondria are truncated) and determined its intracellular localization of HKDC1 under high-and lowglucose (25 or 5 mM, respectively) conditions. Full-length HKDC1 significantly colocalized with the mitochondria, whereas the N-terminal truncated HKDC1 was observed in the cytosolic compartments under both high (Fig. 2B)- and low-glucose conditions and was even found in the nucleus under low-glucose conditions (17) . Furthermore, we discovered that HKDC1 colocalized with VDAC in primary hepatocytes by immunofluorescence (Fig. 2C ) (17) . Taken together, HKDC1 is a low-activity HK that Interdomain salt-bridge site 1: distance between carboxy groups of residues D251 (yellow left) and R800 (yellow right) for HKDC1 and D251 (orange left) and R801 (orange right) for HK1 is 3.6Å apart with a 4.4-Å shift between HKDC1 and HK1. (E) Site 2: distance between carboxy groups of residues R69 (yellow left) and E813 (yellow right) for HKDC1 is 4.1Å and R69 (orange left) and D814 (orange right) is 6.1Å, with a 4.7-Å shift between HKDC1 and HK1. (F) Catalytic active-site distance between D656 (yellow top) and Y620 (yellow bottom) residues for HKDC1 is 5.1Å; D657 (orange top) and Y621 (orange bottom) for HK1 is 7.2Å; and between HKDC1 and HK1 is 8.5Å. All values are means 6 SEM. *P , 0.05, **P , 0.001, where HKDC1 is missing the first 20 amino acids) cultured in 25 mM glucose (19 to 27 GFP + hepatocyte colocalization coefficients were averaged). Hepatocytes were stained for 4 0 ,6-diamidino-2-phenylindole (DAPI) and TMRE, and quantification of colocalization between GFP and TMRE was depicted via calculation of the colocalization coefficient (n = 3 biological replicates). (C) Representative 340 confocal images of transfected primary mouse hepatocytes with EV, FL, and TR, cultured in 25 mM glucose and stained with VDAC antibody (15 to 21 GFP + hepatocyte colocalization coefficients were averaged). Quantification of GFP and VDAC was depicted via calculation of the colocalization coefficient (n = 3 biological replicates). TMRE and VDAC (red channel) and GFP (green channel) signals were analyzed for colocalization using ImageJ. Coloc-2 function and Pearson correlation coefficients were calculated. All values are means 6 SEM. ***P , 0.001, ****P , 0.0001 (one-way ANOVA).
may, in part, be a result of the differences noted in its structure when compared with HK1. Moreover, it appears to colocalize with the mitochondria through its N-terminal mitochondrial localization sequence, similar to HK1 and HK2. Given its low HK activity and its interaction with the mitochondria, the next question that arises is whether hepatic HKDC1 expression alters metabolism in the liver.
Human HKDC1 reduces glycolytic capacity and mitochondrial activity in mouse hepatocytes
To test how overexpression of HKDC1 affects hepatic metabolism, we isolated primary mouse hepatocytes and measured changes in ECAR and OCR after treatment with Ad-HKDC1 or Ad-GFP. Whereas we observed no overt differences in basal glycolysis, we found significantly reduced oligomycin-induced glycolysis (Fig. 3A) , suggesting a defect in glycolytic metabolism. Next, we assessed differences in respiration and found a substantial reduction in OCR after the addition of the uncoupler, FCCP (maximal mitochondrial respiration) for the cells treated with Ad-HKDC1, a sign of mitochondrial dysfunction, relative to Ad-GFP (Fig. 3B) . Thus, the expression of this noncanonical HK impairs both cellular glycolytic capacity and maximal respiration in primary hepatocytes.
To investigate the reduced OCR phenotype further, we used 14 C-labeled glucose to measure directly glucose oxidation after overexpression of HKDC1 in primary hepatocytes and observed a substantial decrease consistent with our OCR finding (Fig. 3C ). This finding is in contrast with what is found after adenoviral-mediated overexpression of GCK in rat hepatocytes, which results in significantly upregulated glucose oxidation (47) . Furthermore, overexpression of GCK in liver of mice leads to hepatic fat accumulation (9, (48) (49) (50) , and it is strongly associated with progression of NAFLD in mice and humans (6) . To examine whether human HKDC1 contributes to the deposition of hepatic fat, we first measured the incorporation of 14 C-labeled glucose into the lipid phase and found that it was significantly increased after overexpression of HKDC1 (17) . However, studies have found that the amount of glucose incorporation into the glycerol backbone of triglycerides is only ;0.5% of metabolized glucose (51) . Therefore, we examined if the Kennedy pathway (the pathway that converts glycerol-3-phosphate that is generated by the preparatory phase of glycolysis into the synthesis of triglycerides) was significantly affected after overexpression of HKDC1, but we found that there were no changes in gene expression of the key enzymes (17) . To more directly assess the rate of lipogenesis, we used radiolabeled acetate. Again, we found that the labeled triglycerides were not altered in hepatocytes that overexpressed HKDC1 (17) . Lastly, we analyzed fatty acid oxidation by 14 C-labeling of palmitic acid and observed a mild but not a substantial reduction (17) .
Given that we found no direct changes in hepatic triglyceride accumulation, but we found reduced OCR and ECAR, we analyzed mitochondrial function by measurement of TMRE intensity as a marker for mitochondrial membrane potential (52) and found that the intensity was also significantly decreased (Fig. 3D) (17) . Interestingly, we also found that overexpression of HKDC1 may play a role in mitochondrial dynamics, as we noted the mitochondrial fusion protein, MFN2, and a mitochondrial fission protein, DRP1, to be significantly upregulated in mouse livers (Fig. 3E and 3F ). These data suggest that the hepatic overexpression of HKDC1 shows signs of mitochondrial dysfunction and does not directly drive lipogenesis under these above conditions.
Acute in vivo overexpression improves glucose tolerance but does not alter hepatic energy storage
To investigate the in vivo effects of overexpression of human HKDC1 in mouse livers, we injected 10 9 adenoviral particles of adenovirus containing human HKDC1 or GFP in wild-type mice, after which, they were euthanized 7 to 10 days later. As illustrated, human HKDC1 was expressed significantly and exclusively in the liver, validating our approach of liver overexpression (Fig. 4A) . In addition, the mouse Hkdc1 expression was not altered in the mice overexpressing human HKDC1 (Fig. 4B) . We next performed an IPGTT to observe the effects of hepatic overexpression. We observed a mild but significantly improved glucose tolerance at the time points 15 and 60 minutes, with a mild but nonsignificant decrease in the AUC. During the IPGTT, no changes in insulin levels at time points 0 and 15 minutes were observed (Fig. 4C) . These results are in line with what we found previously in our aged Hkdc1 +/2 mice, where they had significantly impaired glucose tolerance (12) . In addition, we performed an ITT and found a mild increase in insulin sensitivity in the mice overexpressing HKDC1, but it was not significant (Fig. 4D) . Furthermore, we looked at all of the baseline parameters, including body weight, liver weight, fasting plasma glucose, insulin, triglycerides, and NEFAs, and found no substantial changes (Fig. 4E) . Similarly, we found no changes in hepatic gene expression from various metabolic pathways, including glycolysis (Gapdh, lactate dehydrogenase, pyruvate kinase), citric acid cycle (citrate synthase), gluconeogenesis (glucose-6-phosphatase, phosphoenolpyruvate carboxykinase 1), peroxisome proliferator-activated receptor (Ppar; g, a, b) regulation, fatty acid synthesis (stearoyl-coA desaturase-1, fatty acid synthase), fatty acid oxidation and export (carnitine palmitoyltransferase 1a, fatty acid translocase, fatty acid binding protein 1, microsomal triglyceride Mitochondrial membrane potential measured via fluorescence intensity after overexpression of GFP-tagged EV, FL, and TR in hepatocytes (n = 3, where each n represents hepatocytes isolated from one mouse, and intensity was averaged from a total of 16 to 32 individual hepatocytes). (E) Western blots of mitochondrial fusion proteins MFN1 and MFN2 after in vivo overexpression of Ad-GFP or Ad-HKDC1. Densitometry analysis of MFN1 was normalized to GAPDH, and MFN2 was normalized to a-tubulin (n = 2 to 3 biological replicates). (F) Western blots of mitochondrial fission proteins FIS1, DRP1, and P-DRP1(S616) after in vivo overexpression of Ad-GFP or Ad-HKDC1. Densitometry analysis of FIS1 normalized to a-tubulin, and P-DRP1 and DRP1 total normalized to GAPDH (n = 2 to 3 biological replicates). All values are means 6 SEM. *P , 0.05, **P , 0.001 (Student t test); ***P , 0.0001 (one-way ANOVA). Table with baseline characterization values, including fasting body weight (BW), liver/body weight ratio, fasting plasma glucose, fasting plasma insulin, fasting plasma triglycerides (TGs), and relative fasting plasma NEFA levels (n = 3 to 9 biological replicates). (F) Selected gene expression measured from different metabolic pathways in the livers of mice, 10 days postinjection: lactate dehydrogenase (Ldh), pyruvate kinase (Pklr), Gapdh, citrate synthase (Cs), glucose-6-phosphatase (G6pc), phosphoenolpyruvate carboxykinase 1 (Pck1), peroxisome proliferator-activated receptor g, a, b, (PPARg, PPARa, PPARb, respectively), stearoyl-coA desaturase-1 (Scd1), fatty acid synthase (Fas), carnitine palmitoyltransferase 1a (Cpt1a), fatty acid translocase (Cd36), fatty acid binding protein 1 (Fabp1), and microsomal triglyceride transfer protein (MTP; n = 3 to 6 biological replicates). transfer protein; Fig. 4F ), and the Kennedy pathway genes (17) , nor changes in energy storage, including triglycerides (illustrated with Oil Red O stain and image quantification on the right) and glycogen (illustrated with PAS/DPAS stain and image quantification on the right; Fig. 4G ). Lastly, to confirm this finding, we extracted triglycerides (Fig. 4H ) and glycogen (Fig. 4I) and found no substantial changes in their content, although glycogen trended to be higher with overexpression of HKDC1. These data indicate that acute overexpression of HKDC1 on a normal chow-fed diet does not substantially alter glucose homeostasis or energy storage in the liver.
HKDC1 expression is positively associated with the progression of NAFLD in mice and humans As HKDC1 heterozygous mice have lower hepatic triglycerides, we next investigated the conditions necessary to induce HKDC1 expression, specifically conditions related to fat in the liver. We began by using a publicly available gene database that extensively profiled mouse liver gene expression as a function of age (4 vs 10 weeks), strain (B6 vs BTBR), and obesity (lean vs mice with ob/ob mutation). The ob/ob mutation results in the inability to produce the hormone leptin and thus resulting in obesity. Obese and lean B6 mice are generally established to be diabetes-resistant at all ages, while obese BTBR mice become diabetic by 10 weeks of age (53) . We found increased hepatic Hkdc1 expression in B6 mice (diabetes-resistant mice) after only 4 weeks and in BTBR mice (diabetes-susceptible mice) after 10 weeks of age (Fig. 5A) , which suggested that in mice predisposed to fatty liver, the expression of Hkdc1 may be increased. To determine if there was a positive relationship between hepatic HKDC1 expression and hepatic fat content in humans with various stages of NAFLD, we measured the relative expression of HKDC1 from human liver biopsies that contained varying percentages of fat by qPCR. There was a substantial increase in the expression of hepatic HKDC1 between patients with 10% to 15% of fat and those with .15% fat content (Fig. 5B) . In addition, we found the expression of hepatic HKDC1 to be significantly increased with the progression of liver disease state, where each progressive stage has increased amounts of fibrosis (Fig. 5C ). However, it was difficult to differentiate to what degree expression correlated with steatosis vs inflammation and fibrosis. To gain more insight, we performed immunohistochemistry to detect HKDC1 protein levels in patients with livers that are normal or fatty (steatosis) or contain high levels of inflammation and fibrosis (NASH). We observed darker staining in livers with steatosis but the darkest staining to be in patients with steatohepatitis (Fig. 5D) .
To determine if these results could be recapitulated in mice, we induced obesity and hepatic steatosis in mice with high-fat, high-carbohydrate (glucose or fructose, 25.5% Kcal) diets for 2 to 6 months. Interestingly, Hkdc1 expression was not increased between normal low-fat-fed mice vs a high-fat diet (17) . However, Hkdc1 expression was most significantly elevated in mice on a HF + HFr diet, where there was subsequently more liver triglyceride content than those fed only a HF diet (60 Kcal from fat) or HF + HG (Fig. 5E ) (17) . In addition, the increase of Hkdc1 expression in the livers of mice fed HF + HFr was progressively associated with the accumulation of hepatic fat over time (Fig. 5F) (17) . Thus, HKDC1 expression is also elevated in fatty liver.
To gain further insight if this expression change is related to the stages of fatty liver disease, such as inflammation and fibrosis, we evaluated mice fed on a few additional diets. First, we measured Hkdc1 expression in B6 mice after 8 weeks on a LFCF diet and compared it with an HFCF diet (Fig. 5G) . Mice on the HFCF diet are reported to have marked steatosis after 8 weeks with only some indication of inflammation and fibrosis (54) . As was noted between the normal low-fat-fed mice vs highfat diet, hepatic Hkdc1 expression levels did not change between the two diets (17) . We then measured Hkdc1 expression in mice fed a MSD or MCD [a diet known to increase levels of serum alanine aminotransferase and inflammation (55-57) after just 2 weeks but is coupled with substantial weight loss]. We interestingly found significantly increased Hkdc1 expression in this model (Fig. 5H) . Lastly, we assessed Hkdc1 expression in another model of NASH reported to develop enlarged fatty livers and fibrosis without a substantial loss of body weight and more reflective of the physiology that occurs in humans-the CDA-HFD (0.1%)-and compared it with the control diet, MSD-HFD, after 3 and 6 weeks (58). As was seen with the MCD feeding, we also observed Hkdc1 expression to be significantly increased after just 3 weeks and even more elevated after 6 weeks on the CDA-HFD when compared with the MSD-HFD (Fig. 5I) . Altogether, we conclude that HKDC1 expression may be more associated with NAFLD/NASH, where inflammation and fibrosis are apparent, as suggested here in mice and humans.
Discussion
To date, HKDC1 has been examined mainly in the context of gestational diabetes, as the gene was found to be significantly associated with glycemic traits during pregnancy (10) . In subsequent studies, our group has established this enzyme to contribute to overall cellular HK activity when overexpressed in cancer cells and to be a fifth HK (11) . Here, we report a more comprehensive characterization of the HK abilities of HKDC1 and its influence on hepatocyte metabolism and present observational data that suggest a role in NAFLD. We have shown HKDC1 to function as a low-activity HK that localizes to the mitochondria, at least in hepatocytes, suggesting a role in mitochondrial function. In support of Figure 5 . HKDC1 expression associates with NAFLD conditions. (A) Hkdc1 expression assessed in lean and ob/ob mice at 4 and 10 weeks in B6 and BTBR mouse strains (n = 5 biological replicates). HKDC1 expression measured in liver biopsies of human subjects comparing (B) relative percentage of liver fat with stage 1 fibrosis (n = 4 to 11 biological replicates) and (C) liver stage progression 1 to 3 with varying levels of steatosis (n = 6 to 24 biological replicates). (D) Representative human hepatocyte sections that are normal (I and IV), with steatosis (II and V), and with steatohepatitis and fibrosis (III and VI) were stained with H&E (upper) and anti-HKDC1 antibody (lower; n = 3 for each condition; images were taken at 340). (E) Hepatic Hkdc1 expression measured in B6 mice after 20 weeks on HF, HF + HG (HFHGlu), or HF + HFr (HFHFru) diets beginning at 8 weeks of age (n = 6 to 10 biological replicates). (F) Hepatic Hkdc1 expression measured in mice on HF + HFr diet after 2, 4, and 6 months of feeding, beginning at 8 weeks of age (n = 6 to 10 biological replicates). (G) Hkdc1 expression measured in B6 mice after 8 weeks on either an LFCF (LFLCLFD) diet or an HFCF (HFHCHFD) diet (n = 7 to 9 biological replicates). (H) Hkdc1 expression was measured in B6 mice after 3 weeks on MSD or MCD (n = 3 to 6 biological replicates). (I) Hkdc1 expression was measured in B6 mice after 3 or 6 weeks on either MSD-HFD or CDA-HFD (n = 3 to 7 biological replicates). All data are represented as means 6 SEM. *P , 0.05, **P , 0.001, ***P , 0.0001 (one-way ANOVA).
this, we show that overexpression of HKDC1 in hepatocytes significantly reduces glycolytic capacity, maximal respiration, and glucose oxidation and diminishes mitochondrial membrane potential. Furthermore, acute in vivo overexpression of human HKDC1 mildly improves glucose tolerance. Finally, we report a positive association of HKDC1 expression with NAFLD/NASH, in particular, when inflammation and fibrosis are apparent.
Given the high-sequence and structural similarity with the low Km HK, HK1, we initially predicted HKDC1 to have high glucose phosphorylating activity. In our initial findings, we reported that HKDC1 contributes to overall cellular HK activity, as determined by overexpression and knockdown studies in cancer cell lines (40) ; however, it is known that cancer cells upregulate low Km HK (i.e., HK1 and HK2) expression, and this may have suggested greater HK activity contribution from HKDC1. In our report here, we saw minimal HK activity from HKDC1 when purified and also a mild increase in HK activity in HKDC1-overexpressing MI5-4 CHO cells. Moreover, our in silico structural analysis, comparing HKDC1 and HK1, shows shifts in key amino acids involved in the allosteric and catalytic active site, which may help explain the low activity we see for HKDC1. Future enzymatic structure and function studies will need to be performed to address these amino acid shifts, along with other condition variables.
Although HKDC1 appears to have low HK activity, subcellular localization of HKs is another component believed to be important for regulating the metabolic fate of glucose (42) . High-activity HK isozymes, HK1 and HK2, are reported to regulate metabolism, in part, by their localization to the mitochondria through their interaction with VDAC (13) (14) (15) . VDAC has been reported to play a critical role in mitochondrial function (59, 60) , and interaction with VDAC may have important consequences in hepatic metabolism. For instance, even though HK1 and HK2 are known not to be expressed at high levels in normal liver physiology, HK2 is known to change hepatocyte metabolism through its interaction with VDAC in liver cancer. For example, there are high levels of HK2 in liver cancer and the binding to VDAC is thought to allow minimized product inhibition of HK2 and ultimately act as a driver of the Warburg effect (providing ATP by increased glycolysis, whereas diminishing ATP produced by oxidative phosphorylation) (61) . Little information is known about the expression, localization, and contribution of these HK isozymes in the context of NAFLD. Our finding that a low-activity HK localizes to the mitochondria (particularly colocalizing with VDAC) and hepatocytes overexpressing this enzyme shows signs of mitochondrial dysfunction were surprising and will need to be further explored in its role in hepatic disease. Future studies will evaluate the following: (i) under what conditions HKDC1 localizes to the mitochondria, (ii) if HKDC1 is directly interacting with VDAC in a similar fashion as HK1 and HK2, and (iii) how this binding alters downstream anabolic and catabolic pathways.
The changes noted ex vivo led us to investigate the effects of overexpression of HKDC1 in mouse livers in vivo. We observed that with in vivo overexpression of HKDC1 in the liver, there were corresponding increases in the mitochondrial fusion protein MFN2, mitochondrial fission protein DRP1, and DRP1 Ser616 phosphorylation site, which corresponds with increased mitochondrial fission. Because both MFN2 and DRP1 represent opposite mitochondrial dynamic events, more investigation is needed to assess precisely how HKDC1 is regulating these events. However, the increase in the DRP1 protein and its phosphorylation is more pronounced over MFN2, and the literature suggests that mitochondrial dysfunction (as observed with reduced cellular respiration and ATP) results predominately from upregulation of DRP1 (62, 63) . Furthermore, it has been noted that excessive fragmentation can generate mitochondria with reduced mitochondrial DNA, leading to impaired cellular respiration (64) . Altogether, we note that with overexpression of HKDC1 in hepatocytes, there are signs of mitochondrial dysfunction, as we have found a reduction in maximal respiration, glucose oxidation, and reduced mitochondrial potential that may, in part, be a result of the increased fission protein, DRP1.
Next, given that our heterozygous deletion of Hkdc1 mice had reduced tissue-specific glucose disposal and hepatic triglycerides (12) and that we find signs of mitochondrial dysfunction in overexpressed hepatocytes ex vivo and in vivo, we hypothesized that acute overexpression of hepatic HKDC1 in vivo would alter glucose homeostasis and possibly hepatic energy storage. Although not studied in the context of liver disease, there is evidence suggesting that acute in vivo adenoviral overexpression of HK2 is enough to cause hepatic steatosis after just 7 days (65). We performed a similar method of overexpression but observed no changes in energy storage nor signs of increased de novo lipogenesis (DNL), with only mild changes in glucose homeostasis. These data also contrast with studies reporting that GCK overexpression causes an increase in lipogenic genes in the DNL pathway (48) . Additionally, GCK is strongly associated with hepatic steatosis seen in NAFLD in mice and humans, which is important, given that DNL is essential for the development of steatosis, as one-third of accumulated triglycerides in patients with fatty liver comes from DNL (3, 6) . Although acute overexpression of HKDC1 may not be sufficient to induce any consequential changes in fat accumulation in vivo, future work will assess how chronic overexpression of hepatic HKDC1 alters the hepatic energy metabolism. Moreover, we note that when glucose was provided as a tracer for lipogenesis, HKDC1 overexpression in hepatocytes reveals increased lipogenesis. However, as most of the label is not incorporated in triglycerides as glycerol (51) , enrichment of labeled glycerol in the triglyceride pool is not the best method for determining changes in lipogenesis. This observation is further supported, as evidenced by a lack of change in the Kennedy pathway genes. However, even when provided with labeled acetate, there were no changes in lipogenesis. Future radiolabeled studies are needed to follow how the glucose metabolism is directed in the presence and absence of HKDC1.
Although we did not find overexpression of HKDC1 to drive DNL, as reported for GCK, we did find evidence of heightened HKDC1 expression in conditions defined in NAFLD. Moreover, it is clear that HKDC1 expression and protein levels are elevated in livers with steatosis but much more so in human patients whose livers have progressed to the steatohepatitis stage (see Fig. 5D ) (17) . Additionally, we were able to recapitulate these findings in mouse models of NASH. Interestingly, the diets that induced Hkdc1 expression were the models in which the diets were not simply ones that caused hepatic steatosis (as the HFCF diet after 8 weeks of feeding) but rather, diets that induce inflammation and fibrosis (MCD and CDA-HFD), which is indicative of a more advanced stage of NAFLD. Some potential explanations have been proposed to describe the changes that occur from simple steatosis to more progressive stages, such as NASH. For example, one hypothesis proposes the "two-hit" model, where the first "hit" is fat infiltration into the liver (steatosis) and the second hit is from free radicals, resulting from oxidative stress, thereby causing inflammation (66) . The particular mechanisms describing this transition are still under investigation (51, (67) (68) (69) but suggest a link with mitochondrial dysfunction. Given that we observe signs of mitochondrial dysfunction in hepatocytes with HKDC1 overexpression, as well as in vivo changes to mitochondrial fusion and fission proteins with no direct contribution to triglyceride synthesis, it may be that HKDC1 plays an important role in the progression of hepatosteatosis into more advanced stages of NAFLD through these processes. Supporting our data, two studies that reported whole RNA gene changes in NAFLD illustrate that HKDC1 is indeed more expressed in advanced stages of NASH compared with liver with simple steatosis (70, 71) . However, a limitation of our work is that our viral-overexpression model only results in overexpression for a few weeks, and therefore, we could not directly use it to test the role of HKDC1 in the development of NAFLD through different diets (as NAFLD development takes many weeks). Additionally, sex differences need to be explored, as a result of our previous findings in female mice (12) and as HKDC1 was identified from genetic studies in pregnancy (10) .
Future studies will examine the effects of hepatic knockout and overexpression of Hkdc1 in various NASH models to elucidate whether HKDC1 plays a protective effect against the overproduction of hepatic triglyceride accumulation or whether it drives the progression to NASH. Overall, this work has taken a step toward the understanding of the potential role of the HK isozyme HKDC1 in the liver, where more studies are needed to clarify its role in NAFLD and other physiological and pathological states.
